Straits Times Index
3,292.93 -3.96 (-0.12%) S&P 500
5,127.79 +63.59 (+1.26%) Dow
38,675.68 +449.98 (+1.18%) Nasdaq
16,156.33 +315.33 (+1.99%) Bitcoin USD
64,113.96 +184.72 (+0.29%) CMC Crypto 200
1,334.16 +57.18 (+4.48%)
CLNN Jan 2025 3.000 call
| Previous close | 0.0600 |
| Open | 0.0700 |
| Bid | 0.0500 |
| Ask | 0.7000 |
| Strike | 3.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.0600 - 0.0700 |
| Contract range | N/A |
| Volume | |
| Open interest | 120 |
GlobeNewswireIBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etherington
LOS ANGELES, May 01, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies with the investment community, today announces that Rob Etherington, President, Director and CEO of late clinical-stage biopharmaceutical company Clene Inc. (NASDAQ: CLNN), recently appeared on From Lab to Launch, a podcast sharing the inspiring stories of founders, investors, scientists, engineers and pioneers in the life sciences sector. The podcast, ho
Simply Wall St.Bullish Clene Insiders Loaded Up On US$9.58m Of Stock
Quite a few insiders have dramatically grown their holdings in Clene Inc. ( NASDAQ:CLNN ) over the past 12 months. An...
GlobeNewswireEvidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
Long term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p<0.05)Significantly improved clinical outcomes associated with long-term daily oral CNM-Au8® 30 mg treatment (change from original baseline; p<0.05)Long-term CNM-Au8 treatment, encompassing up to three years, was well-tolerated; no significant safety findings were observedFirst Phase 2 clini
